用于复发性艰难梭菌感染的粪便微生物群移植供体及粪便样本的实验室检测
Laboratory Testing of Donors and Stool Samples for Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection.
作者信息
Woodworth Michael H, Neish Emma M, Miller Nancy S, Dhere Tanvi, Burd Eileen M, Carpentieri Cynthia, Sitchenko Kaitlin L, Kraft Colleen S
机构信息
Division of Infectious Diseases, Emory University, Atlanta, Georgia, USA.
Emory University, Atlanta, Georgia, USA.
出版信息
J Clin Microbiol. 2017 Apr;55(4):1002-1010. doi: 10.1128/JCM.02327-16. Epub 2017 Jan 11.
Abstract
Fecal microbiota transplantation is an efficacious and inexpensive therapy for recurrent infection, yet its safety is thought to depend on appropriate fecal donor screening. FDA guidance for regulation of this procedure is in flux, but screening and manufacture of fecal material from asymptomatic donors present many challenges to clinical laboratories. This minireview summarizes FDA regulatory changes, principles of donor selection, and recommended laboratory screening practices for fecal microbiota transplantation.
摘要
粪便微生物群移植是一种治疗复发性感染的有效且廉价的疗法，但其安全性被认为取决于对粪便供体的适当筛选。美国食品药品监督管理局（FDA）对该程序的监管指南正在不断变化，但对无症状供体粪便材料的筛选和制备给临床实验室带来了诸多挑战。本综述总结了FDA的监管变化、供体选择原则以及粪便微生物群移植推荐的实验室筛选方法。
相似文献
1
Laboratory Testing of Donors and Stool Samples for Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection.用于复发性艰难梭菌感染的粪便微生物群移植供体及粪便样本的实验室检测
J Clin Microbiol. 2017 Apr;55(4):1002-1010. doi: 10.1128/JCM.02327-16. Epub 2017 Jan 11.
2
Establishing a Fecal Microbiota Transplant Service for the Treatment of Clostridium difficile Infection.建立用于治疗艰难梭菌感染的粪便微生物群移植服务。
Clin Infect Dis. 2016 Apr 1;62(7):908-14. doi: 10.1093/cid/civ994. Epub 2015 Nov 30.
3
Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.造血干细胞移植受者复发性艰难梭菌感染的粪便微生物群移植
Transpl Infect Dis. 2016 Aug;18(4):628-33. doi: 10.1111/tid.12550. Epub 2016 Jul 5.
4
Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review.粪便微生物群移植中粪便供体选择与筛查的挑战：综述
Gut Microbes. 2017 May 4;8(3):225-237. doi: 10.1080/19490976.2017.1286006. Epub 2017 Jan 27.
5
Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation.完全微生物群植入对于粪便微生物群移植后复发性艰难梭菌感染的恢复并非必不可少。
mBio. 2016 Dec 20;7(6):e01965-16. doi: 10.1128/mBio.01965-16.
6
Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection.使用通用供体降低复发性艰难梭菌感染的粪便微生物群移植的成本和复杂性。
Adv Ther. 2019 Aug;36(8):2052-2061. doi: 10.1007/s12325-019-00974-x. Epub 2019 Jun 1.
7
Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.复发性艰难梭菌感染和/或溃疡性结肠炎患者单次供体粪便微生物群移植的纵向微生物组分析
PLoS One. 2018 Jan 31;13(1):e0190997. doi: 10.1371/journal.pone.0190997. eCollection 2018.
8
[Fecal microbiota transplantation, a novel therapy for recurrent Clostridium difficile infection].[粪便微生物群移植，一种治疗复发性艰难梭菌感染的新疗法]
Ned Tijdschr Tandheelkd. 2016 Sep;123(9):406-9. doi: 10.5177/ntvt.2016.09.16146.
9
[Indication selection and clinical application strategies of fecal microbiota transplantation].[粪便微生物群移植的适应证选择与临床应用策略]
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 May 25;23(5):509-515. doi: 10.3760/cma.j.cn.441530-20200110-00015.
10
Effect of Aging on the Composition of Fecal Microbiota in Donors for FMT and Its Impact on Clinical Outcomes.衰老对粪菌移植供体粪便微生物群组成的影响及其对临床结局的影响。
Dig Dis Sci. 2017 Apr;62(4):1002-1008. doi: 10.1007/s10620-017-4449-6. Epub 2017 Feb 8.
引用本文的文献
1
Unraveling gut microbiome alterations and metabolic signatures in hereditary transthyretin amyloidosis.揭示遗传性转甲状腺素蛋白淀粉样变性中的肠道微生物群改变和代谢特征。
Microbiol Spectr. 2025 Jul;13(7):e0230224. doi: 10.1128/spectrum.02302-24. Epub 2025 May 23.
2
FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial.原发性硬化性胆管炎粪便微生物群移植（FARGO）：一项随机、多中心、IIa期、安慰剂对照试验的研究方案
BMJ Open. 2025 Jan 6;15(1):e095392. doi: 10.1136/bmjopen-2024-095392.
3
Campylobacter Infection Introduced Following Fecal Microbiota Transplantation.粪便微生物群移植后引发的弯曲杆菌感染
Cureus. 2024 Jun 17;16(6):e62541. doi: 10.7759/cureus.62541. eCollection 2024 Jun.
4
Current perspectives on fecal microbiota transplantation in inflammatory bowel disease.炎症性肠病中粪便微生物群移植的当前观点
Indian J Gastroenterol. 2024 Feb;43(1):129-144. doi: 10.1007/s12664-023-01516-8. Epub 2024 Feb 9.
5
Intestinal stem cells and gut microbiota therapeutics: hype or hope?肠道干细胞与肠道微生物群疗法：炒作还是希望？
Front Med (Lausanne). 2023 Jul 21;10:1195374. doi: 10.3389/fmed.2023.1195374. eCollection 2023.
6
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.复发性艰难梭菌感染：当前的临床管理及基于微生物群的治疗方法
BioDrugs. 2023 Nov;37(6):757-773. doi: 10.1007/s40259-023-00617-2. Epub 2023 Jul 26.
7
High carriage rate of extended-spectrum β-lactamase Enterobacterales and diarrheagenic Escherichia coli in healthy donor screening for fecal microbiota transplantation.在粪便微生物群移植的健康供体筛查中，产超广谱β-内酰胺酶肠杆菌科细菌和致泻性大肠杆菌的携带率较高。
Eur J Clin Microbiol Infect Dis. 2023 Sep;42(9):1103-1113. doi: 10.1007/s10096-023-04644-3. Epub 2023 Jul 20.
8
Cytomegalovirus in donors for fecal microbiota transplantation, the phantom menace?供体粪便微生物群移植中的巨细胞病毒，幽灵般的威胁？
PLoS One. 2023 Jun 29;18(6):e0287847. doi: 10.1371/journal.pone.0287847. eCollection 2023.
9
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).粪便微生物移植治疗复发性艰难梭菌（艰难梭菌）。
Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871. doi: 10.1002/14651858.CD013871.pub2.
10
Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy.粪菌移植治疗溃疡性结肠炎：一种不断发展的疗法。
Crohns Colitis 360. 2020 Aug 15;2(4):otaa067. doi: 10.1093/crocol/otaa067. eCollection 2020 Oct.
本文引用的文献
1
Detection of Clostridium difficile in Feces of Asymptomatic Patients Admitted to the Hospital.医院收治的无症状患者粪便中艰难梭菌的检测
J Clin Microbiol. 2017 Feb;55(2):403-411. doi: 10.1128/JCM.01858-16. Epub 2016 Nov 16.
2
A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection.复发性艰难梭菌感染相关成本的综合研究
Infect Control Hosp Epidemiol. 2017 Feb;38(2):196-202. doi: 10.1017/ice.2016.246. Epub 2016 Nov 7.
3
Ensuring the safe and effective FDA regulation of fecal microbiota transplantation.确保美国食品药品监督管理局对粪便微生物群移植进行安全有效的监管。
J Law Biosci. 2015 Jul 6;2(2):396-415. doi: 10.1093/jlb/lsv032. eCollection 2015 Jul.
4
Systematic Review: Adverse Events of Fecal Microbiota Transplantation.系统评价：粪便微生物群移植的不良事件
PLoS One. 2016 Aug 16;11(8):e0161174. doi: 10.1371/journal.pone.0161174. eCollection 2016.
5
Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia.澳大利亚粪便微生物群移植治疗复发性艰难梭菌感染的经济学评估
J Gastroenterol Hepatol. 2016 Dec;31(12):1927-1932. doi: 10.1111/jgh.13402.
6
Cost Averted With Timely Fecal Microbiota Transplantation in the Management of Recurrent Clostridium difficile Infection in Alberta, Canada.加拿大艾伯塔省通过及时进行粪便微生物群移植治疗复发性艰难梭菌感染所避免的成本。
J Clin Gastroenterol. 2016 Oct;50(9):747-53. doi: 10.1097/MCG.0000000000000494.
7
Optimal screening and donor management in a public stool bank.公共粪便库中的最佳筛选和供体管理。
Microbiome. 2015 Dec 17;3:75. doi: 10.1186/s40168-015-0140-3.
8
Donor Recruitment for Fecal Microbiota Transplantation.粪便微生物群移植的供体招募
Inflamm Bowel Dis. 2015 Jul;21(7):1600-6. doi: 10.1097/MIB.0000000000000405.
9
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook.2015年粪便微生物群移植最新进展：适应证、方法、机制及展望
Gastroenterology. 2015 Jul;149(1):223-37. doi: 10.1053/j.gastro.2015.05.008. Epub 2015 May 15.
10
Burden of Clostridium difficile infection in the United States.美国艰难梭菌感染的负担
N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913.
Zotero 插件